Abstract:A specific variant in the PNPLA3 gene is a known genetic risk factor for NAFLD. We validated an antibody recognizing the PNPLA3 protein and used it to show that the PNPLA3 protein is primarily located on hepatic lipid droplets in human liver samples from patients with NAFLD. We also showed that PNPLA3 protein levels are associated with NAFLD and that carriers of the specific PNPLA3 gene variant had higher hepatic levels of the protein compared to subjects without the mutation. The hypothesis that increased hepatic PNPLA3 protein levels in subjects carrying the mutation contributes to their increased risk of NAFLD is supported. In nonalcoholic fatty liver disease (NAFLD) the patatin‐like phospholipase domain‐containing 3 (PNPLA3) rs738409 variant is a contributor. In mice, the Pnpla3 148M variant accumulates on lipid droplets and probably leads to sequestration of a lipase cofactor leading to impaired mobilization of triglycerides. To advance our understanding of the localization and abundance of PNPLA3 protein in humans, we used liver biopsies from patients with NAFLD to investigate the link to NAFLD and the PNPLA3 148M genotype. We experimentally qualified an antibody against human PNPLA3. Hepatic PNPLA3 protein fractional area and localization were determined by immunohistochemistry in biopsies from a well‐characterized NAFLD cohort of 67 patients. Potential differences in hepatic PNPLA3 protein levels among patients related to degree of steatosis, lobular inflammation, ballooning, and fibrosis, and PNPLA3 I148M gene variants were assessed. Immunohistochemistry staining in biopsies from patients with NAFLD showed that hepatic PNPLA3 protein was predominantly localized to the membranes of small and large lipid droplets in hepatocytes. PNPLA3 protein levels correlated strongly with steatosis grade (p = 0.000027) and were also significantly higher in patients with lobular inflammation (p = 0.009), ballooning (p = 0.022), and significant fibrosis (stage 2–4, p = 0.014). In addition, PNPLA3 levels were higher in PNPLA3 rs738409 148M (CG, GG) risk allele carriers compared to 148I (CC) nonrisk allele carriers (p = 0.0029). Conclusion: PNPLA3 protein levels were associated with increased hepatic lipid content and disease severity in patients with NAFLD and were higher in PNPLA3 rs738409 (148M) risk allele carriers. Our hypothesis that increased hepatic levels of PNPLA3 may be part of the pathophysiological mechanism of NAFLD is supported.

Accumulation of PNPLA3 on Lipid Droplets is the Basis of Associated Hepatic Steatosis

PNPLA3, CGI‐58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice

PNPLA3(148M) Promotes Hepatic Steatosis by Interfering with Triglyceride Hydrolysis Through a Gain-of-Function Mechanism

Lipid Droplet Targeting of ABHD5 and PNPLA3 I148M is required to promote liver steatosis

The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics

PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein

PNPLA3-I148M is a Neomorph that Interferes with Two Primary Hepatic Triglyceride Clearance Pathways

PNPLA3(I148M) Inhibits Lipolysis by Perilipin-5-Dependent Competition with ATGL

Role of patatin-like phospholipase domain-containing 3 on lipid-induced hepatic steatosis and insulin resistance in rats.

PNPLA3 variant M148 causes resistance to starvation‐mediated lipid droplet autophagy in human hepatocytes

PNPLA3-I148M Variant Promotes the Progression of Liver Fibrosis by Inducing Mitochondrial Dysfunction

PNPLA3 148M/M Is More Susceptible to Palmitic Acid-Induced Endoplasmic Reticulum Stress-Associated Apoptosis in HepG2 Cells

The Propensity of the Human Liver to Form Large Lipid Droplets Is Associated with PNPLA3 Polymorphism, Reduced INSIG1 and NPC1L1 Expression and Increased Fibrogenetic Capacity

Hepatic patatin‐like phospholipase domain‐containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans

Fatty Acids Promote Fatty Liver Disease Via the Dysregulation of 3-Mercaptopyruvate Sulfurtransferase/hydrogen Sulfide Pathway.

Pdia3 Knockdown Exacerbates Free Fatty Acid-Induced Hepatocyte Steatosis and Apoptosis

Mouse patatin-like phospholipase domain-containing 3 influences systemic lipid and glucose homeostasis.

The Ubiquitin E3 Ligase BFAR Promotes Degradation of PNPLA3.

Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis.

PNPLA3 Rs139051 is Associated with Phospholipid Metabolite Profile and Hepatic Inflammation in Nonalcoholic Fatty Liver Disease

PNPLA 3 I 148 M Variant in Nonalcoholic Fatty Liver Disease : Demographic and Ethnic Characteristics and the Role of the Variant in Nonalcoholic Fatty Liver Fibrosis